High-dose methylprednisolone no benefit for women with preeclampsia, platelet counts <150 × 109/L
FRIDAY, June 10, 2016 (HealthDay News) — High-dose methylprednisolone does not prevent platelet decline in women with preeclampsia and platelet counts below 150 × 109/L, according to a study published in the July issue of Obstetrics & Gynecology.
Olivier Pourrat, M.D., Ph.D., from the Centre d’Investigation Clinique in Poitiers, France, and colleagues conducted a randomized trial of 180 mg methylprednisolone or placebo administered in divided doses over 36 hours to women admitted for preeclampsia and platelet counts below 150 × 109/L. Thirty-six women were randomized to receive methylprednisolone and 34 to receive placebo.
The researchers found that 83 percent of the active group and 85 percent of the placebo group had platelet counts above 100 × 109/L at 36 hours after the first dose of study medication (relative risk, 0.98; 95 percent confidence interval, 0.80 to 1.20). One woman allocated to methylprednisolone had hyperglycemia, which was the only potentially study-related adverse event.
“In women with preeclampsia and platelet counts under 150 × 109/L, methylprednisolone was not effective in maintaining platelet counts above 100 × 109/L,” the authors write.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
